SYRS News

While markets got a rough start to the week on the heels of the UK Referendum vote, both US and global markets rebounded sharply during the remainder of the week. The S&P 500 closed the week at 2,103, just ten points shy of its close before the vote. VC-backed Twilio (TWLO) continued to trade well, now 127% above its IPO price. For the month of June, the...read more

Syros Pharmaceuticals, which is developing gene expression therapies based on non-coding DNA research, raised $50 million by offering 4 million shares at $12.50, below the range of $14 to $16. Syros Pharmaceuticals plans to list on the Nasdaq under the symbol SYRS. Cowen & Company and Piper Jaffray acted as lead managers on the deal....read more

In the last week before Independence Day weekend, there are a few small IPOs to cap off a second quarter that was much improved from the lackluster first quarter. Syros Pharmaceuticals looks to continue the trend of insider buying on biotechs. Tactile Systems and Gemphire Therapeutics plan to make a second effort on...read more

Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. Insiders intend to purchase $35 million worth of shares in the offering. At the midpoint of the proposed range, Syros...read more